St. John's, Canada Clinical Trials

A listing of St. John's, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Galderma Investigational Site
 (0.5 away) Contact site
  • 95 views
  • 16 Jul, 2021
  • +458 other locations
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Galderma Investigational Site 8000
 (0.5 away) Contact site
  • 21 views
  • 16 Jul, 2021
  • +470 other locations
A Study to Assess the Efficacy Safety and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Tp0006 50384
 (1130.5 away) Contact site
  • 15 views
  • 11 Jul, 2021
  • +49 other locations
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored. …

systemic therapy
plaque psoriasis
risankizumab
arthritis
apremilast
Karma Clinical Trials /ID# 230339
 (3.5 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +61 other locations
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line …

pomalidomide
measurable disease
lenalidomide
daratumumab
vasectomy
Health Sciences Center
 (1.6 away) Contact site
  • 79 views
  • 24 Jan, 2021
  • +47 other locations
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human) Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses …

Health Sciences Centre
 (1.6 away) Contact site
  • 695 views
  • 02 Jun, 2021
  • +70 other locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide …

pomalidomide
electrophoresis
line of therapy
serum proteins
progressive disease
Memorial Hospital of Newfoundland
 (1.6 away) Contact site
  • 50 views
  • 07 May, 2021
  • +23 other locations
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency

nesiritide
bypass graft
iron
natriuretic peptide
cardiac resynchronization therapy
Health Sciences Centre
 (1.6 away) Contact site
  • 5316 views
  • 22 Jul, 2021
  • +365 other locations
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Recombinant human parathyroid hormone, also known as if rhPTH(1-84), is a medicine to treat people with Hypothyroidism. The main aim of this study is to learn if rhPTH(1-84) can improve symptoms in adults with hypoparathyroidism. In this study, participants will receive 1 of 2 treatments: rhPTH(1-84) or a placebo. A …

muscle cramps
tsh level
ergocalciferol
hypocalcemia
replacement therapy
Eastern Health - Health Sciences Center- General Hospital
 (1.6 away) Contact site
  • 200 views
  • 03 Feb, 2021
  • +49 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

infarct
acute coronary syndrome
arterial disease
diabetes
myocardial infarction
1240060 - Health Sciences Centre
 (1.6 away) Contact site
  • 1118 views
  • 21 Jul, 2021
  • +3430 other locations